EC Grants Marketing Authorisation for IntraBio’s Aqneursa

Why It Matters

The authorisation provides the first disease‑modifying therapy for NPC in Europe, potentially improving outcomes for a rare, fatal neurodegenerative disorder and opening market opportunities for IntraBio.

Key Takeaways

• EU approval covers patients ≥6 years, ≥20 kg, alone or with miglustat.
• Phase III trial showed significant neurological improvement after 12 weeks.
• Disease progression slowed by 118 % over one year versus natural history.
• Aqneursa received orphan status, enhancing incentives for rare‑disease development.
• Flatulence identified as most common side effect in clinical studies.

Pulse Analysis

Niemann‑Pick disease type C (NPC) is a lysosomal storage disorder that manifests with progressive neurodegeneration, ataxia, and premature death, affecting roughly 1 in 100,000 individuals worldwide. Until now, therapeutic options in Europe have been limited to symptomatic management with miglustat, which does not halt disease progression. The European Commission’s decision to authorize Aqneursa marks the first disease‑modifying treatment available to European patients, offering clinicians a tool that directly targets the metabolic dysfunction underlying NPC. This regulatory milestone also reflects growing confidence in rare‑disease approvals across the EU.

Aqneursa (levacetylleucine) is a modified amino‑acid that stabilises cellular energy pathways in the central nervous system. In a double‑blind, placebo‑controlled Phase III crossover trial, patients receiving the drug experienced statistically significant improvements on the Scale for the Assessment and Rating of Ataxia after just 12 weeks, and an observed 118 % reduction in annual disease progression compared with natural‑history controls. The therapy’s orphan‑medicinal‑product designation granted IntraBio tax incentives and market exclusivity, facilitating a faster path to market and encouraging further investment in NPC research.

The approval of Aqneursa underscores the European Medicines Agency’s willingness to embrace innovative, small‑molecule solutions for ultra‑rare conditions. For IntraBio, the EU label opens a market of roughly 3,000 potential patients, with reimbursement negotiations likely to follow national health‑technology assessments. Moreover, the data package sets a precedent for future submissions targeting other lysosomal storage disorders, where metabolic modulation may prove effective. Patients, advocacy groups, and clinicians can now anticipate broader access, while investors watch closely for similar orphan‑drug opportunities emerging from the EU regulatory landscape.